Kidney Cancer

Protocol #SponsorProtocol Title
NCT02420821

Hoffmann-La Roche
WO29637, 2014-004684-20
A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination with Bevacizumab Versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma

Kidney cancer has been notoriously resistant to conventional chemotherapy and radiation therapy. The most common types of kidney cancer are now treatable with a variety of angiogenesis-directed therapies, including Avastin, Sutent, Nexavar, Votrient, and Inlyta, or mTOR-directed therapies (Torisel and Afinitor). Immunotherapy, previously with Interleukin and Interferon, showed activity, but with significant toxicity.

Current trials are examining investigational PD1/ PDL-1 inhibitor immunotherapies alone or in combination with angiogenesis inhibitors.